CClinicalTrials.gg
CompletedNCT07462845VLADUpdated Mar 10, 2026

Agents Effect Under Visible Light on Caucasian, Asian and Darker Skin Types

An observational study in Visible Light Exposure on Healthy Back Skin, sponsored by L'Oreal. Completed at 1 site in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by L'Oreal · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
66
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The study intends to get knowledge on pigmentation induced by visible light on Asian/Chinese skin type and darker skin type, and to evaluate and to compare with a non-treated control zone and between them, the efficacy of photoprotective effect of different products after visible light exposure, between [400-700nm], on these skin types compared to Caucasian for whom the investigators already got knowledge.

Read the detailed description

The main objective of this study is:

- To assess the ability of protective agents to prevent the pigmentation under visible light exposures (VL) in healthy volunteers with different skin type (caucasian, asian and darker skin) by skin colorimetry (Delta E) and clinical evaluation.

The secondary objectives are:

  • To assess the local tolerance and safety of the products under VL exposure by recording adverse events and safety
  • To assess the safety of the different Investigational Products.
02

Conditions studied

  • Visible Light Exposure on Healthy Back Skin

Keywords

  • pigmentation
  • visible light
03

In context

Lead sponsor

L'Oreal is the lead sponsor of 25 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Healthy male and female volunteers from 18 to 50 yo, with Fitzpatrick III to VI and an ITA° between -30° to +36° at screening.

Inclusion criteria

  • To be enrolled in this study, all subjects must satisfy all the following criteria at study entry:

    1. Healthy female or male volunteer from 18 to 50 years old
    2. Caucasian Skin type III-IV according to the Fitzpatrick classification OR Asian Skin type III-IV (chinese population) according to the Fitzpatrick classification OR Darker Skin type VI according to the Fitzpatrick classification
    3. Average ITA° (Individual Typologic Angle calculated value) on the back between 24° and 36° at screening and inclusion visits with an allowed difference of ± 2° between screening and inclusion visits, for Caucasian volunteers OR Average ITA° (Individual Typologic Angle calculated value) on the back between 24° and 36° at screening and inclusion visits with an allowed difference of ± 2° between screening and inclusion visits, for Asian volunteers OR Average ITA° (Individual Typologic Angle calculated value) on the back less than -30° at screening and inclusion visits with an allowed difference of ± 2° between screening and inclusion visits, for Darker skin volunteers
    4. Uniform skin color over the four zones (difference in ITA° between each zone should not be more than 4°)
    5. Absence of freckles, naevi, hypo or hyper pigmented regions, hairs and marks of bronzing on the investigational area on the back
    6. Female subject of childbearing potential, who is not sexually active, or using an effective contraceptive method* for at least one month before the beginning of the study, and throughout the study or menopausal female (with absence of menstruations for less than one year) or post-menopausal female (with absence of menstruations for more than one year)

      *Effective contraceptive methods: sexually active female of childbearing potential should either be surgically sterile (oophorectomy, hysterectomy or tubal ligation), or should use a medically accepted contraceptive regimen: systemic contraceptive (oral, implant, injection), diaphragm or cervical cap with intravaginal spermicide, intravaginal device, intrauterine device (IUD), condom with spermicide

    7. Female of childbearing potential or menopausal female (with absence of menstruations for less than one year) willing to undergo urine pregnancy test
    8. Subject willing and able to fulfil the study requirements and schedule
    9. Subject informed about the study objectives and procedures, and able to understand them
    10. Subject who has given written informed consent

Exclusion criteria

Exclusion Criteria:

  • If any following non-inclusion criterion applies, the subject must not be included in the study:

    1. Subject who is pregnant or lactating or who is planning to become pregnant during the study
    2. Subject with BMI > 30 except if, according to the investigator's judgement, the subject is able to follow the study procedure without compromising his/her health
    3. Having planned UV exposure of the investigational area (sunlight or sunbeds) throughout the study
    4. Having used sunbeds or had excessive sun exposure of the investigational area within the 3 months before inclusion
    5. Having sunburn (erythema) on the back
    6. Dermatological disorders affecting the investigational area (presence of naevi, freckles, excess hair or uneven skin tones, vitiligo, photo-dermatological problems)
    7. History of skin cancer
    8. History of abnormal response to sun
    9. Presence of recent suntan (according to Investigator opinion) or photo-test marks
    10. History of allergy, hypersensitivity, or any serious reaction to any cosmetic product
    11. Any concomitant medical condition that may interfere with the study conduct in the opinion of the investigator
    12. Having used within the month before inclusion any systemic medication for more than 5 consecutive days (e.g. steroidal and non-steroidal anti-inflammatory drugs, corticoids, insulin, antihistamines, antihypertensive, antibiotics such as quinolone, tetracycline, thiazides, fluoroquinolones)
    13. Having used within the month before inclusion any medication known to cause abnormal responses to UV exposure (e.g. vitamin A derivative, psoralen, aminolevulinic acid derivatives, etc.), or having planned to use these medications during the study
    14. Having used within the 3 months before inclusion any depigmenting / whitening or pro-pigmenting topical treatments, or any systemic treatment that would interfere with the study assessments (anti-inflammatory drugs, corticoids, retinoids, hydroquinone, etc.) or having planned to use these treatments during the study
    15. Having used, within the past 6 months, any physical treatment including laser or phototherapy (PUVA, IPL, PDT…) on the investigational area, or having planned to use these treatments during the study
    16. Having planned to perform intensive sport (> 5 hours per week) or to swim or to practice hammam/sauna during the study
    17. Subject who declares to be deprived of freedom by administrative or legal decision
    18. Subject who cannot be contacted by telephone in case of emergency
    19. Subject having participated within the 30 days before inclusion or currently participating in another clinical study
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
66 participants (actual)
Patient registry
No

Groups and cohorts

  • Caucasian

    22 volunteers Caucasian skin with a skin phototype III or IV

  • Asian

    22 volunteers Asian skin with a skin phototype III-IV

  • Darker skin

    22 volunteers darker skin with a skin phototype VI

06

What researchers measure

Primary outcomes

  1. Skin color measurement with ITA° angle

    The device Chromameter® (non-invasive assessment) will be used to measure the skin color, between the exposed zone (ZE) and non-exposed zone (ZNE), through the ITA° angle calculation, using formula \[Arc Tangent ((L\* - 50) / b\*)\] 180 / p. The L\* defines the perceptual lightness from black at 0 to white at 100. The b\* represents the blue-yellow opponents, with negative numbers toward blue and positive toward yellow.

    Time frame: From enrollment at Day 1 to the end of study at Day 12

  2. Skin pigmentation contrast

    The device Chromameter® (non-invasive assessment) will be used to measure the skin contrast, between the exposed zone (ZE) and non-exposed zone (ZNE), through the Delta E calculation, using formula √ (ΔL\*2+Δa\*2+Δb\*2)). The L\* defines the perceptual lightness from black at 0 to white at 100. The a\* axis is relative to the green-red opponent colors, with negative values toward green and positive values toward red. The b\* represents the blue-yellow opponents, with negative numbers toward blue and positive toward yellow.

    Time frame: From enrollment at Day 1 to the end of study at Day 12

Secondary outcomes

  1. Visual scoring of pigmentation

    A trained investigator will visually score the skin pigmentation, using L'Oreal pigmentation scale : 0 Absence 1. Barely visible 2. Very pale brown - 3. Very pale brown 4. Very pale brown + 5. Pale brown - 6. Pale brown 7. Pale brown + 8. Brown - 9. Brown 10. Brown + 11. Pronounced brown - 12. Pronounced brown 13. Pronounced brown +

    Time frame: From enrollment at Day 1 to the end of study at Day 12

  2. Visual scoring of erythema

    A trained investigator will visually score the skin erythema, using L'Oreal erythema scale : 0 Absence 1. Barely visible 2. Very pale pink - 3. Very pale pink 4. Very pale pink + 5. Pale pink - 6. Pale pink 7. Pale pink + 8. Pink - 9. Pink 10. Pink + 11. Pronounced pink - 12. Pronounced pink 13. Pronounced pink +

    Time frame: From enrollment at Day 1 to the end of study at Day 12

07

Study locations

1 site
  • L'Oréal
    Aulnay-sous-Bois, 93600, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07462845
Lead sponsor
L'Oreal
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Sep 5, 2022
Primary completion
Dec 15, 2022
Completion
Dec 15, 2022
Last update
Mar 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion